Chronic sarcoidosis (CS) is often unresponsive to usual treatments. Melatonin, an immunoregulatory drug, was employed in CS patients in whom usual treatments were ineffective or induced severe side effects. Melatonin was given for 2 yr (20 mg/day in the first year, 10 mg/day in the second year) to 18 CS patients. Pulmonary function tests, chest X rays, pulmonary computed tomography, Ga(67) scintigraphy and angiotensin-converting enzyme (ACE) were assayed at baseline and in the follow-up. Normalization of ACE, improvement of pulmonary parameters and resolution of skin involvement were found in the patients given melatonin. After 24 months of melatonin therapy, hylar adenopathy completely resolved in eight patients and parenchymal lesions were markedly improved in all patients; in the five patients with reduced diffusion capacity of the lung for carbon monoxide, the values normalized after 6 months of therapy and remained stable until month 24. After 24 months, Ga(67) pulmonary and extra-pulmonary uptake was totally normalized in seven patients and, at month 12 months, ACE was normalized in six patients in which the values were high at the baseline. Skin lesions, present in three patients, completely disappeared at month 24 months. No side effects were experienced and no disease relapse was observed during melatonin treatment. Melatonin may be an effective and safe therapy for CS when other treatments fail or cause side effects.

Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarciodosis / MOGGI PIGNONE A; DEL ROSSO A; FIORI G; MATUCCI CERINIC M; BECUCCI A; TEMPESTINI A; LIVI R; GENERINI S; GRAMIGNA L; BENVENUTI C; A. CAROSSINO; CONFORTI L; PERFETTO F. - In: JOURNAL OF PINEAL RESEARCH. - ISSN 0742-3098. - ELETTRONICO. - 4:(2006), pp. 95-100.

Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarciodosis

MOGGI PIGNONE, ALBERTO;DEL ROSSO, ANGELA;FIORI, GINEVRA;MATUCCI CERINIC, MARCO;BECUCCI, AURELIANO;TEMPESTINI, ALESSIO;LIVI, RICCARDO;GENERINI, SERGIO;CAROSSINO, ANNA MARIA;CONFORTI, MARIA LETIZIA;PERFETTO, FEDERICO
2006

Abstract

Chronic sarcoidosis (CS) is often unresponsive to usual treatments. Melatonin, an immunoregulatory drug, was employed in CS patients in whom usual treatments were ineffective or induced severe side effects. Melatonin was given for 2 yr (20 mg/day in the first year, 10 mg/day in the second year) to 18 CS patients. Pulmonary function tests, chest X rays, pulmonary computed tomography, Ga(67) scintigraphy and angiotensin-converting enzyme (ACE) were assayed at baseline and in the follow-up. Normalization of ACE, improvement of pulmonary parameters and resolution of skin involvement were found in the patients given melatonin. After 24 months of melatonin therapy, hylar adenopathy completely resolved in eight patients and parenchymal lesions were markedly improved in all patients; in the five patients with reduced diffusion capacity of the lung for carbon monoxide, the values normalized after 6 months of therapy and remained stable until month 24. After 24 months, Ga(67) pulmonary and extra-pulmonary uptake was totally normalized in seven patients and, at month 12 months, ACE was normalized in six patients in which the values were high at the baseline. Skin lesions, present in three patients, completely disappeared at month 24 months. No side effects were experienced and no disease relapse was observed during melatonin treatment. Melatonin may be an effective and safe therapy for CS when other treatments fail or cause side effects.
2006
4
95
100
MOGGI PIGNONE A; DEL ROSSO A; FIORI G; MATUCCI CERINIC M; BECUCCI A; TEMPESTINI A; LIVI R; GENERINI S; GRAMIGNA L; BENVENUTI C; A. CAROSSINO; CONFORTI...espandi
File in questo prodotto:
File Dimensione Formato  
Pignone, J Pineal Res 2006.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 188.33 kB
Formato Adobe PDF
188.33 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/251495
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact